MedGenome Labs offers clonoSEQ test for MRD - ETHealthWorld

The test helps to detect MRD even at low levels offering a prognostic value to clinicians, helping them to assess how patients respond to treatment or if any change in disease management is required.

Bengaluru: MedGenome announced it is offering Adaptive Biotechnologies next-generation sequencing (NGS)-based clonoSEQ Assay to assess minimal residual disease (MRD) in patients with multiple myeloma… [+1426 chars]

full article...